Diabetes is a major chronic disease that requires attention. Diabetic
foot ulcers are a common and serious complication of type 1 and type 2
diabetes. Between 19% and 34% of all people with diabetes will develop
a foot ulcer at some time in their lives. Patients with diabetic foot ulcers
often underestimate the impact of the ulcers or even fail to recognize
them. However, these ulcers can lead to a variety of complications, such
as infections that require hospitalization and, in the most severe cases,
even amputation, which can have a significant negative impact on a patient's
The management of diabetic foot ulcers remains a major therapeutic challenge.
Platelet-derived growth factor-β (PDGF-β) has been developed
to treat local therapy ulcers in uninfected diabetic feet. In addition
to this, recombinant human basic fibroblast growth factor (rhbFGF) and
recombinant human epidermal growth factor (rhEGF) are also considered to
be promising adjunctive therapies.
With the intensive study of the wound healing process in recent years,
researchers have found that many growth factors are closely associated
with repair cells and play a key role in wound repair in particular. Fibroblast
growth factor (FGF) is one of them. FGF-2 is also known as the basic fibroblast
growth factor (bFGF). rhbFGF is a recombinant form of bFGF. bFGF is one
of the most widely studied FGFs. In recent years, several studies have
shown that bFGF does have a positive effect on the healing of diabetic
Expression of bFGF in angiogenesis, neurogenesis, and neuronal survival.
In a diabetic mouse model, the healing of skin wounds was accelerated and
epithelial formation was increased by controlled release of bFGF. In addition,
controlled release of bFGF induced apoptosis of trabecular fibroblasts
and myofibroblasts, thereby reducing scar formation during healing.
rhEGF is a 53 amino acid peptide that can stimulate the proliferation
of fibroblasts, keratin-forming cells, and vascular endothelial cells.
It also contributes to the formation of scar tissue. The mechanism of action
is based on the interaction with specific receptors located on specific
cell membranes. rhEGF was developed through recombinant DNA technology
and has been produced in yeast by biotechnological methods.
rhEGF is an effective and safe treatment for diabetic foot ulcers. Statistics
show that rhEGF has a higher rate of complete healing than placebo and
also significantly reduces the time to complete healing. Subgroup analysis
based on different routes of administration showed that topical application
of rhEGF had a better therapeutic effect than intra-lesion injection. And
in most trials, the incidence of adverse events was low.
Many clinical studies have also demonstrated that rhbFGF and rhEGF can
promote ulcer healing and can be used in the treatment of diabetic foot
ulcers with significant therapeutic benefits. Therefore, Creative BioMart offers our customers high-quality rhbFGF and rhEGF products. In this way,
we seek to assist you in conducting research into the treatment of diabetic
foot ulcers and potentially developing new treatment pathways based on
this research. This is what we expect to see and is the fundamental purpose
of our products for our customers, and we look forward to seeing improvements
in the lives of people with diabetic foot ulcers. Please feel free to
for the latest news on our products.